Impact of Concomitant Proton Pump Inhibitor Use on the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancer Types.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
621 patients with cancer treated with ICIs between January 2015 and June 2021.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] This study underscores the potential risks associated with the concomitant use of PPIs and ICIs in cancer treatment. The findings suggest that careful consideration is necessary when prescribing PPIs to patients undergoing ICI therapy.
[BACKGROUND] Proton pump inhibitors (PPIs) are commonly prescribed medications that may influence the gut microbiome and impact the efficacy of immune checkpoint inhibitors (ICIs) in cancer treatment.
- 95% CI 1.752-2.037
- 연구 설계 cohort study
APA
Niu C, Zhang J, et al. (2025). Impact of Concomitant Proton Pump Inhibitor Use on the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancer Types.. Journal of the National Comprehensive Cancer Network : JNCCN, 23(11), 437-443. https://doi.org/10.6004/jnccn.2025.7070
MLA
Niu C, et al.. "Impact of Concomitant Proton Pump Inhibitor Use on the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancer Types.." Journal of the National Comprehensive Cancer Network : JNCCN, vol. 23, no. 11, 2025, pp. 437-443.
PMID
41101342
Abstract
[BACKGROUND] Proton pump inhibitors (PPIs) are commonly prescribed medications that may influence the gut microbiome and impact the efficacy of immune checkpoint inhibitors (ICIs) in cancer treatment.
[PATIENTS AND METHODS] We conducted a large retrospective cohort study using the TriNetX database, encompassing >35,621 patients with cancer treated with ICIs between January 2015 and June 2021. Patients were stratified into 2 cohorts: those receiving ICIs with concurrent PPI use and those without PPI use.
[RESULTS] Concomitant PPI use was associated with significantly higher mortality rates in patients treated with PD-1 inhibitors across multiple cancer types, including melanoma (hazard ratio [HR], 1.889; 95% CI, 1.752-2.037); breast cancer (HR, 1.512; 95% CI, 1.345-1.701); urothelial carcinoma (HR, 1.406; 95% CI, 1.276-1.551); colorectal cancer (HR, 1.310; 95% CI, 1.187-1.445); hepatocellular carcinoma (HR, 1.413; 95% CI, 1.238-1.614); renal cancer (HR, 1.490; 95% CI, 1.375-1.614); Hodgkin lymphoma (HR, 1.646; 95% CI, 1.212-2.236); head and neck cancers (HR, 1.402; 95% CI, 1.259-1.561); and lung cancer (HR, 1.308; 95% CI, 1.184-1.445). Similar trends were observed with PD-L1 inhibitors, where PPI use correlated with increased mortality in melanoma (HR, 1.657; 95% CI, 1.049-2.617); breast cancer (HR, 1.584; 95% CI, 1.297-1.934); renal cancer (HR, 1.380; 95% CI, 1.059-1.799); and urothelial carcinoma. ICU admissions were more frequent among PPI users across different cancer types and ICI treatments.
[CONCLUSIONS] This study underscores the potential risks associated with the concomitant use of PPIs and ICIs in cancer treatment. The findings suggest that careful consideration is necessary when prescribing PPIs to patients undergoing ICI therapy.
[PATIENTS AND METHODS] We conducted a large retrospective cohort study using the TriNetX database, encompassing >35,621 patients with cancer treated with ICIs between January 2015 and June 2021. Patients were stratified into 2 cohorts: those receiving ICIs with concurrent PPI use and those without PPI use.
[RESULTS] Concomitant PPI use was associated with significantly higher mortality rates in patients treated with PD-1 inhibitors across multiple cancer types, including melanoma (hazard ratio [HR], 1.889; 95% CI, 1.752-2.037); breast cancer (HR, 1.512; 95% CI, 1.345-1.701); urothelial carcinoma (HR, 1.406; 95% CI, 1.276-1.551); colorectal cancer (HR, 1.310; 95% CI, 1.187-1.445); hepatocellular carcinoma (HR, 1.413; 95% CI, 1.238-1.614); renal cancer (HR, 1.490; 95% CI, 1.375-1.614); Hodgkin lymphoma (HR, 1.646; 95% CI, 1.212-2.236); head and neck cancers (HR, 1.402; 95% CI, 1.259-1.561); and lung cancer (HR, 1.308; 95% CI, 1.184-1.445). Similar trends were observed with PD-L1 inhibitors, where PPI use correlated with increased mortality in melanoma (HR, 1.657; 95% CI, 1.049-2.617); breast cancer (HR, 1.584; 95% CI, 1.297-1.934); renal cancer (HR, 1.380; 95% CI, 1.059-1.799); and urothelial carcinoma. ICU admissions were more frequent among PPI users across different cancer types and ICI treatments.
[CONCLUSIONS] This study underscores the potential risks associated with the concomitant use of PPIs and ICIs in cancer treatment. The findings suggest that careful consideration is necessary when prescribing PPIs to patients undergoing ICI therapy.
MeSH Terms
Humans; Proton Pump Inhibitors; Immune Checkpoint Inhibitors; Female; Retrospective Studies; Neoplasms; Middle Aged; Aged; Male; Treatment Outcome
같은 제1저자의 인용 많은 논문 (5)
- Long-term outcomes of TIPS assessed by MRI features in patients with portal hypertension and hepatocellular carcinoma: A retrospective study.
- Gastrointestinal and Hepatobiliary Safety of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes.
- Plant polyphenols in gastric cancer: Nature's healing touch.
- Evaluating the Long-Term Benefits of Medications for Alcohol Use Disorder in Alcohol-Associated Cirrhosis.
- Coexisting inflammatory bowel disease in primary sclerosing cholangitis is associated with higher colorectal cancer and transplant risk.